A low guideline-directed medical therapy score at discharge increased the risk of all-cause mortality or heart failure rehospitalization (HR 1.432) in patients with HFrEF and renal dysfunction.
Observational (n=626)
No
Does a high guideline-directed medical therapy (GDMT) score improve the composite of all-cause mortality or HF rehospitalization in patients with HFrEF and renal dysfunction?
A higher guideline-directed medical therapy (GDMT) score at discharge is independently associated with improved long-term prognosis in patients with HFrEF and renal dysfunction, highlighting the importance of optimizing medical therapy even when limited by renal impairment.
Effect estimate: HR 1.432 (95% CI 1.087-1.886)
p-value: p=0.011
Objective To examine the association between the guideline-directed medical therapy (GDMT) intensity at discharge and the long-term prognosis in patients with heart failure (HF) with a reduced ejection fraction (HFrEF) and renal dysfunction.
Kishihara et al. (Thu,) conducted a observational in Heart failure with reduced ejection fraction (HFrEF) and renal dysfunction (n=626). Low guideline-directed medical therapy (GDMT) score (≤4) vs. High GDMT score (>4) was evaluated on Composite of all-cause mortality or heart failure rehospitalization (HR 1.432, 95% CI 1.087-1.886, p=0.011). A low guideline-directed medical therapy score at discharge increased the risk of all-cause mortality or heart failure rehospitalization (HR 1.432) in patients with HFrEF and renal dysfunction.